- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06238570
Validation of Donor Oocytes Semi-automated Vitrification (GAVIDO)
Validation of Semi-automatic Oocyte Vitrification by the GAVI® Machine in Medically Assisted Reproduction With Oocyte Donation
Oocyte vitrification is an effective method of freezing which has been authorized in France since 2011. The arrival of this technique has led to real improvements in the survival rate of oocytes after warming compared to that observed after slow freezing, a method previously applied. Oocytes reheated after vitrification show excellent results in terms of vitality and recovery of cellular functionality. Indeed, the fertilization rates observed after using warmed and fertilized oocytes in Assisted Reproduction Technology (ART) by intracytoplasmic sperm injection (ICSI) are similar to those obtained with fresh oocytes.
However, the manual vitrification techniques used until now involve a learning curve and a potential variability of the completion time depending on the operator and the number of oocytes to be vitrified.
Oocyte vitrification is a key step to optimize the chances of pregnancy in ART after using these oocytes. However, manual vitrification requires a learning curve, is technician-dependent and requires significant technical time.
A semi-automatic vitrification device (GAVI®, Merck), which recently appeared on the market, has demonstrated its effectiveness in terms of speed of production and reproducibility of vitrification of embryos obtained in ART. To our knowledge, no study has analyzed the effectiveness of semi-automatic vitrification (GAVI®, Merck) on survival and oocyte quality after warming. It would therefore be interesting to evaluate the effectiveness of this automaton on oocyte vitrification in the context of oocyte donation and to determine the impact of semi-automatic vitrification on oocytes compared to manual vitrification.
The main objective of this study is to demonstrate the non-inferiority of vitrification semi-automated device (Gavi) of oocytes with regard to the oocyte survival rate, compared to the manual technique used in ART.
The investigator will compare the effectiveness of semi-automated vitrification device with the manual technique, in terms of ART results by comparing the fertilization rates, the number and quality of embryos obtained as well as the implantation rates in oocyte recipient patients. This study will then allow clinical application of the most efficient protocol for oocyte vitrification in the context of oocyte donation. A cost/effectiveness study will be carried out.
Study Overview
Status
Intervention / Treatment
Detailed Description
The oocytes will be stored in closed devices (Rapid I® straws for the manual vitrification protocol or pods® in cassettes for the semi-automatic vitrification protocol) in liquid nitrogen. All samples are anonymized in the context of oocyte donation by the medically assisted procreation (PMA) department of Clermont-Ferrand University Hospital, according to the method usually used.
The oocyte survival rate will be evaluated by the service technician or biologist. This survival rate corresponds to the ratio between the number of oocytes intact 2 hours after warming and able to be microinjected with a spermatozoon (ICSI), and the number of oocytes heated, after vitrification. We will compare the oocyte survival rate after vitrification and semi-automatic warming vs. after manual vitrification.
The investigator will compare the effectiveness of ART with oocyte donation during semi-automatic vitrification of oocytes compared to the manual technique, with regard to:
- Oocyte functional quality after warming evaluated by the fertilization rate of oocytes after ICSI
Early development of embryos:
- the number of embryos cleaved on the 2nd day of culture from vitrified oocytes, the blastulation rate defined by the ratio between the number of blastocysts obtained (Gardner classification on the 5th day of culture) and the total number of cleaved embryos.
These parameters will be assessed daily during the embryo reading by a technician or a biologist from the ART department.
We will also compare the effectiveness of ART with oocyte donation during the semi-automatic vitrification of oocytes compared to the manual technique, with regard to:
- The implantation rate of embryos from vitrified oocytes, defined by the ratio between the number of embryo sacs observed (6th week of amenorrhea) and the number of embryos transferred
- The rate of miscarriages in oocyte recipients. These parameters will be evaluated by a biologist from the ART department after the results of the beta hCG of the patients and the performance of the ultrasound at the 6th week of amenorrhea by the gynecologists of the ART department.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63000
- Recruiting
- CHU de Clermont-Ferrand
-
Contact:
- Lise Laclautre
- Phone Number: +33473754963
- Email: llaclautre_perrier@chu-clermontferrand.fr
-
Principal Investigator:
- Laure CHAPUT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Egg donor
- Oocyte puncture for donation
- Good quality ovarian reserve (Antral follicle count evaluated by ultrasound: CFA ≥ 7)
- Negative serology status (HIV, hepatitis B and C, syphilis, CMV and HTLV)
- Absence of symptoms or COVID contact
- Absence of genetic contraindication to egg donation
- Woman able to give informed consent to participate in research
- Woman affiliated to a social security scheme
Exclusion Criteria:
- Decline to participate
- Pregnant and lactating woman
- Person under guardianship, curatorship, deprivation of liberty, protection of justice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Manual vitrification (using Vitrolife system)
The vitrification of the oocytes will be carried out by an authorized technician according to the manual protocol validated and used routinely.
|
The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
|
Active Comparator: Semi-automatic vitrification of oocytes using the GAVI® automaton (Merck)
The vitrification of the oocytes will be carried out using the GAVI® automaton
|
This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification. The oocytes will be stored in closed cassettes in liquid nitrogen |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oocyte survival
Time Frame: two years after the inclusion
|
Oocyte survival after semi-automated vitrification by the GAVI® device compared to the manual technique (Vitrolife) with egg donation.
A warmed oocyte that has survived can then be used in AMP by ICSI technique.
|
two years after the inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of ART with egg donation after oovcytes semi-automated vitrification
Time Frame: two years after vitrification
|
|
two years after vitrification
|
Study the costs and cost-effectiveness
Time Frame: at the end of the study 24 months
|
Study the costs and cost-effectiveness of ART by egg donation, during semi-automatic oocyte vitrification and during manual technique, from a hospital point of view.
|
at the end of the study 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AOI 2020 CHAPUT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fertility
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Sandstone DiagnosticsCompletedFertility, Male | Sub-Fertility, MaleUnited States
-
Fundación Santiago Dexeus FontRecruiting
-
University of NottinghamCompleted
-
Ava AGUniversity Hospital, Zürich; Empa, Swiss Federal Laboratories for Materials... and other collaboratorsCompleted
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Fundació Privada EuginCompleted
-
Main Line Fertility CenterMerck Sharp & Dohme LLCCompletedFertilityUnited States
-
Northwell HealthTerminated
-
Michigan State UniversityMichigan Department of Community HealthCompleted
Clinical Trials on Vitrolife system
-
University Hospital, Clermont-FerrandVitrolifeUnknown
-
The University of Hong KongKwong Wah HospitalCompletedIn Vitro Fertilization | SubfertilityHong Kong
-
University Hospital, GhentCompleted
-
Weill Medical College of Cornell UniversityVitrolifeTerminatedInfertilityUnited States
-
University Hospital, GhentRecruitingMiscarriage, Recurrent | IVF | Embryo LossBelgium
-
Erasme University HospitalCompletedHuman Embryo CryopreservationBelgium
-
The Egyptian IVF-ET CenterCompleted
-
South Valley UniversityIbn Sina Hospital; Qena Fertility Center, Qena, EgyptUnknownImprovement of Embryo Transfer Technique | Improvement of Implantation
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil